Compare GENB & LMAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GENB | LMAT |
|---|---|---|
| Founded | 2018 | 1983 |
| Country | United States | United States |
| Employees | N/A | 655 |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 2.2B |
| IPO Year | N/A | 2006 |
| Metric | GENB | LMAT |
|---|---|---|
| Price | $14.44 | $97.78 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 5 |
| Target Price | $23.20 | ★ $105.80 |
| AVG Volume (30 Days) | ★ 413.4K | 223.4K |
| Earning Date | 05-11-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 0.93% |
| EPS Growth | N/A | ★ 30.57 |
| EPS | N/A | ★ 0.68 |
| Revenue | N/A | ★ $249,602,000.00 |
| Revenue This Year | N/A | $14.21 |
| Revenue Next Year | $16.58 | $8.88 |
| P/E Ratio | ★ N/A | $146.62 |
| Revenue Growth | N/A | ★ 13.53 |
| 52 Week Low | $11.00 | $79.01 |
| 52 Week High | $16.75 | $118.01 |
| Indicator | GENB | LMAT |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 35.56 |
| Support Level | $11.52 | $82.65 |
| Resistance Level | $16.32 | $99.95 |
| Average True Range (ATR) | 1.34 | 4.66 |
| MACD | -0.13 | -0.63 |
| Stochastic Oscillator | 49.25 | 11.95 |
Generate Biomedicines Inc is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company's single operating segment is engaged in the field of generative biology by using machine learning for drug discovery and development through the programming of novel protein therapeutics. Its product candidates include: GB-0895, GB-4362, and GB-5267. Through the company's Generate Platform, it can generate medicines on demand across multiple therapeutic modalities with unprecedented speed representing a fundamental shift in drug discovery.
LeMaitre Vascular Inc is a provider of medical devices and human tissue cryopreservation services mainly used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices to address the needs of vascular surgeons and, to a lesser extent, other specialties such as cardiac surgeons, general surgeons, and neurosurgeons. Its diversified portfolio consists of branded products used in arteries and veins that are well known to vascular surgeons. It operates across the Americas, Europe, the Middle East and Africa, and Asia Pacific, with the majority of its revenue generated from the Americas.